Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Drug industry on tenterhooks as Maryland price-gouging law nears

share with twitter share with LinkedIn share with facebook
share via e-mail
09/15/2017 | 01:20pm CET
A pharmacy employee dumps pills into a pill counting machine as she fills a prescription while working at a pharmacy in New York

As U.S. consumer outrage grows over prescription drug prices, state authorities and patient advocates in Maryland are preparing to enforce the nation's first law designed to punish drugmaker price-gouging.

The state Attorney General's office said it will field complaints and investigate "unconscionable increases" in essential generic medicines when the closely watched law takes effect Oct. 1.

Drugmakers fear the Maryland law will embolden other states and are seeking a court injunction. Both sides made their arguments on Thursday before a U.S. District Court judge in Baltimore, who could decide on an injunction in the coming days.

Anticipating the law will survive the legal challenge, the Attorney General's office said it is working with health economists at Johns Hopkins University to identify price spikes, which are not made public by drugmakers. Patient advocacy groups are urging consumers to report increased costs for their medicines. Maryland Citizens' Health Initiative will add an option to report price gouging to its website.

Pharmaceutical companies have so far dodged stricter federal oversight despite growing outrage over price hikes. Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) raised the price of heart medications Isuprel by about 720 percent and Nitropress by 310 percent, after acquiring them in 2015. Mylan NV (>> Mylan NV) raised the price of its life-saving EpiPen six-fold between 2008 and 2016.

But states, struggling to cover rising healthcare costs, are taking up the fight. At least 176 bills on pharmaceutical pricing and payment have been introduced this year in 36 states, according to the National Conference of State Legislatures.

Maryland's law is the most aggressive legislation to be passed so far, and allows the state to levy fines and order a reversal of price increases.

The Association for Accessible Medicines, a generic industry trade group that filed the lawsuit, argues that the law is unconstitutional because it does not define price-gouging and amounts to intervention by an individual state in interstate commerce.

"The issue of drug pricing is a national issue ... not something that should be handled piecemeal in 50 different ways," said Jeff Francer, general counsel for the trade group which represents companies like Teva Pharmaceutical Industries Ltd (>> Teva Pharmaceutical Industries Limited) and Novartis AG's (>> Novartis) Sandoz unit.

Maryland Attorney General Brian Frosh said that states have a well-defined role to play in policing "unconscionable" business activity against consumers, especially when they have no other recourse. He cited consumer contracts for telephone service, which are non-negotiable.


The measure applies only to older, off-patent drugs. Generic copies of branded products, usually much cheaper than the originals, account for around 89 percent of U.S. prescription volume, but only 26 percent of total drug spending, according to Quintiles IMS Holdings Inc (>> Quintiles IMS Holdings Inc).

But price spikes on some critical treatments have hit consumers hard. The U.S. Government Accountability Office last year found that 315 generic drugs more than doubled in price since 2010.

Maryland's Frosh said the aim is to deter future steep increases. Before the law was passed, drugmakers had suggested setting a minimum increase of 100 percent as a threshold for investigation, but state officials feared that would incentivize price hikes up to that point, according to Frosh’s office.

Several states have passed laws requiring drugmakers to disclose price increases, but the Maryland law is one of a few drawing the most attention from the drug industry.

Nevada has been sued by two industry trade groups after passing in June a law requiring diabetes drugmakers to justify price increases above a certain amount.

Ohio voters next year will decide on a ballot measure requiring drugmakers to offer state groups the same discounts given to the federal Department of Veterans Affairs. A similar measure failed in California last year, but the state's legislature this week approved a drug pricing bill requiring drugmakers to justify price increases over 16 percent in a two-year period. It now goes to the state's governor for a final decision.

"The states have decided to try and deal with this on their own," said David Gibbons an attorney at Hyman, Phelps & McNamara, which specializes in pharmaceutical and biotechnology companies.

(Reporting by Deena Beasley in Los Angeles; Editing by Michele Gershberg and Lisa Shumaker)

By Deena Beasley

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MYLAN NV
01/10 Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg
01/08 MYLAN : to Complete $1 Billion Share Repurchase Plan
2017 MYLAN : Adds to U.S. Women's Healthcare Portfolio With FDA Approval of First Gen..
2017 MYLAN : Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA,..
2017 WORKDAY : Factory Mutual Insurance Company Decreased Mylan N V (MYL) Stake; Work..
2017 MYLAN : to Present at the 36th Annual J.P. Morgan Healthcare Conference
2017 Perrigo lines up bid for Merck's consumer health unit - sources
2017 MYLAN : Announces the U.S. Patent and Trademark Appeal Board Institutes Inter Pa..
2017 MYLAN : Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to ..
More news
News from SeekingAlpha
01/19 U.S. Justice Department may seek damages from generic drugmakers for price-fi..
01/19 WALL STREET BREAKFAST : Investors Calm As Government Shutdown Looms
01/18 Generic firms under pressure on possible hospital drug-making venture
01/18 Hospital groups planning to enter generic drugs business
01/16 Greenlight Capital's (David Einhorn) Q4 2017 Letter
Financials ($)
Sales 2017 11 990 M
EBIT 2017 3 405 M
Net income 2017 846 M
Debt 2017 13 882 M
Yield 2017 -
P/E ratio 2017 20,46
P/E ratio 2018 14,53
EV / Sales 2017 3,25x
EV / Sales 2018 2,89x
Capitalization 25 060 M
Duration : Period :
Mylan NV Technical Analysis Chart | MYL | NL0011031208 | 4-Traders
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 48,1 $
Spread / Average Target 2,9%
EPS Revisions
Heather M. Bresch Chief Executive Officer & Director
Rajiv Malik President & Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV10.56%25 060
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132